Acne vulgaris
Conditions
Interventions
GroupA:BPO gel Monotherapy group
GroupB:BPO gel +Ozenoxacin lotion (Concomitant therapy group)
GroupC:Ozenoxacin lotion +Adapalene gel (Concomitant therapy group)
Sponsors
Non-Profit Organization Health Institute Research of Skin
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with moderate or severe acne vulgaris (6 to 30 inflammatory rashes on the right or left half of the face) 2) Patients who provided written informed consent after receiving an explanation of the details of the study 3) Patients aged 13 years old or older at the time informed consent was provided For patients younger than 20 years old, representatives (parents, etc.) are required to provide informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients who had received treatment for acne vulgaris within one month of the start of the study 2) Patients in whom the study drug is contraindicated 3) Patients with continuous use of non-steroidal anti-inflammatory drugs (ibuprofen, etc.) 4) Pregnant women, those who may be pregnant, lactating women, and women who hope to become pregnant during the study period 5) Patients who were considered inappropriate for the study by an investigator 6) Patients who had participated in other clinical studies within 6 months of the start of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease in the number of inflammatory rashes / during 12 weeks of observation period | — |
Countries
Japan
Contacts
Public ContactYoshitaka Ogaki
EBC&M LLC. Project planning & Development department
Outcome results
None listed